Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 139 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo atorvastatin Clear all
Completed Phase 2 Interventional Results available

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

NCT00335504
View directory record Official record
Conditions
Colon Cancer, Precancerous Condition, Rectal Cancer
Interventions
oligofructose-enriched inulin, sulindac, placebo, atorvastatin calcium, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 12, 2026, 4:59 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
View directory record Official record
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 12, 2026, 4:59 PM EDT
Terminated Phase 1 Interventional Results available

Clinical Utility of Endothelial Dysfunction in PAD

NCT00491751
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
atorvastatin, ascorbic acid, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Not applicable Interventional Results available

Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

NCT00375518
View directory record Official record
Conditions
Thoracic Surgery
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

NCT00127218
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
any statin, niacin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

NCT00094172
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

NCT01342211
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, Statin, PF-04950615 (RN316), Satin
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
38
States / cities
Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 12, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

NCT00249899
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 12, 2026, 4:59 PM EDT
Recruiting Phase 4 Interventional

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

NCT06632379
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Atorvastatin 10 mg, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

NCT00701883
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, MBX-8025, Atorvastatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

NCT01236365
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin Placebo
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 20 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
5
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

NCT00529542
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Lipitor, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

NCT01351025
View directory record Official record
Conditions
HIV-1 Infection
Interventions
atorvastatin, placebo for atorvastin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Not applicable Interventional Results available

Statin Therapy to Improve Atherosclerosis in HIV Patients

NCT00965185
View directory record Official record
Conditions
Cardiovascular Disease, HIV, Atherosclerosis, Inflammation, Statins, HMG-CoA, HIV Infections
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

NCT03051100
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
11
States / cities
Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 12, 2026, 4:59 PM EDT
Not listed Phase 2 Interventional

Statins and Breast Cancer Biomarkers

NCT00914017
View directory record Official record
Conditions
Breast Cancer
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
San Francisco, California • Newark, Delaware • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Not applicable Interventional Results available

Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

NCT00791648
View directory record Official record
Conditions
Acute Kidney Injury, Post-Operative Delirium, Icu Delirium, Acute Renal Failure, Delirium
Interventions
atorvastatin, placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

A Study in People With High Cholesterol

NCT00133380
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PPAR alpha, atorvastatin, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Fayetteville, Arkansas • Stockton, California • Highlands Ranch, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2007 · Synced Sep 12, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional Results available

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

NCT02850081
View directory record Official record
Conditions
Carotid Artery Stenosis, Strokes
Interventions
Statin, Atorvastatin, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 12, 2026, 4:59 PM EDT
Enrolling by invitation Phase 2 Interventional

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

NCT05826912
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Atorvastatin Calcium, Minocycline Hydrochloride, Candesartan Cilexetil, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
San Francisco, California • Indianapolis, Indiana • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Imaging of Coronary Plaques in Participants Treated With Evolocumab

NCT03570697
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Evolocumab, Placebo, Statin therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 12, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Ezetimibe, Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 12, 2026, 4:59 PM EDT